Last reviewed · How we verify
NCT07312799
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
Phase 1 trial testing Treatment A(AD-2321) in Hypertension in 41 participants. Not yet recruiting.
11 February 2026
Quick facts
| Lead sponsor | Addpharma Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 27 January 2026 |
| Primary completion | 11 February 2026 |
| Estimated completion | 26 February 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Treatment A(AD-2321) — full drug profile →
- Treatment B(AD-2322) — full drug profile →
- Treatment C(AD-2321+AD-2322) — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
Addpharma Inc. — full company profile →
Who can join
Adults 19 to 64, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07312799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Addpharma Inc. trials
Trials by the same sponsor.
- NCT07444385 — A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects · Phase 1 · recruiting
- NCT07385235 — Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' · Phase 1 · recruiting
- NCT07312773 — A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C · Phase 1 · not yet recruiting
- NCT06884085 — A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B · Phase 1 · completed
- NCT06858865 — A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07312799 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Addpharma Inc.
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07312799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing